SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-22-000165
Filing Date
2022-09-12
Accepted
2022-09-12 07:07:52
Documents
1
Period of Report
2022-09-09

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_166298085835189.html 4  
1 FORM 4 wf-form4_166298085835189.xml 4 3497
  Complete submission text file 0001725160-22-000165.txt   5039
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O TRILLIUM THERAPEUTICS INC. 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address
Skvarka Jan (Reporting) CIK: 0001838042 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 221237363